Published in final edited form as:

Cell Biochem Biophys. 2007 ; 47(1): 87–98.

Prevention of Hypertension in DOCA-Salt Rats by an Inhibitor of Soluble Epoxide Hydrolase

David Loch¹, Andrew Hoey², Christophe Morisseau³, Bruce O. Hammock³, and Lindsay Brown^{1,*}

1 Department of Physiology and Pharmacology, School of Biomedical Sciences, The University of Queensland 4072, Australia

2 Centre for Biomedical Research, Faculty of Sciences, University of Southern Queensland, Toowoomba 4350, Australia

3 Department of Entomology and Cancer Research Center, University of California, Davis, CA USA 95616

Abstract

Cyclooxygenase and lipoxygenase metabolism of arachidonic acid produces compounds important in cardiovascular control. Further, arachidonic acid can be metabolised by cytochrome p450 to produce epoxyeicosatrienoic acids (EETs). These derivatives are inactivated by soluble epoxide hydrolase (sEH). The potential role of these EETs in hypertension and cardiac remodelling has been determined using the selective sEH inhibitor, N-adamantyl-N'-dodecylurea (ADU), in deoxycorticosterone acetate (DOCA)-salt hypertensive rats. Experiments were performed on male Wistar rats following uninephrectomy alone (UNX rats) or uninephrectomy with administration of DOCA (25 mg every fourth day subcutaneously) and 1% NaCl in drinking water (DOCA-salt rats). ADU (10 mg/kg/d subcutaneously) was administered for 2 wk starting 2 wk after surgery. Cardiovascular structure and function were determined using organ wet weights, histological analysis of collagen and inflammation, isolated heart and thoracic aortic ring preparations, and electrophysiological measurements. DOCA-salt hypertensive rats developed hypertension, hypertrophy, perivascular and interstitial fibrosis, endothelial dysfunction, and prolongation of the cardiac action potential duration within 4 wk. Administration of ADU prevented the further increase in systolic blood pressure and left-ventricular wet weight and normalized endothelial function. ADU treatment did not change inflammatory cell infiltration, collagen deposition, or cardiac action potential duration. EETs may be involved in the development of hypertension and endothelial dysfunction in DOCA-salt rats, but not in excessive collagen deposition or electrophysiological abnormalities.

Index Entries

DOCA-salt rats; epoxyeicosatrienoic acids (EETs); hypertension; remodeling; soluble epoxide hydrolase (sEH)

INTRODUCTION

Three major pathways utilizing cyclooxygenase, lipoxygenase, or cytochrome p450 are recognized for the metabolism of arachidonic acid, with cyclooxygenase metabolites such as the prostaglandins and thromboxanes accepted as important modulators of the cardiovascular system (1). Cytochrome p450 metabolizes arachidonic acid in the presence of NADPH and

*Author to whom all correspondence and reprint requests should be addressed. E-mail: l.brown@uq.edu.au

oxygen to epoxyeicosatrienoic acids (EETs) and hydroxy-eicosatetraenoic acids (HETEs). EETs can be further metabolized to dihydroxyeicosatrienoic acids (DHETs) by soluble epoxide hydrolase (sEH) to attenuate or abrogate their biological responses (2). The EETs and HETEs may be important mediators in hypertension, cardiovascular disease, and inflammation (2).

Increasing EET concentrations in vivo represents a potential approach to the treatment of cardiovascular disease. After release from endothelial cells, EETs have multiple physiological effects in the cardiovascular system, including stimulation of calcium-activated potassium channels, hyperpolarization and relaxation of vascular smooth muscle cells (3), protection of the myocardium from ischemia-reperfusion injury (4), fibrinolytic activity (5), and decreased vascular smooth muscle cell migration (6). EETs also impede adhesion molecule expression on endothelial cells via inhibition of cytokine-induced activation of the transcription factor nuclear factor (NF)- κ B (7). Further, altered cytochrome p450 metabolism may induce the development of hypertension and cardiovascular remodeling (8–11). Cytochrome p450 metabolism of arachidonic acid was altered in response to deoxycorticosterone acetate (DOCA) treatment (12), dietary salt loading (13–15), and in the remaining kidney after uninephrectomy (16).

Understanding the roles of EETs requires the availability of selective and stable inhibitors of the cytochrome p450 pathway of the metabolism of arachidonic acid. Substituted urea compounds are structural analogs of EET that act as potent, competitive, and tight binding inhibitors of sEH (17). These compounds attenuated vascular smooth muscle cell proliferation (18), decreased systolic blood pressure in the spontaneously hypertensive rat (SHR) and angiotensin II-infusion model (19–21) and protected the kidney (22), all with an associated elevation of EET concentrations.

This study has administered the selective sEH inhibitor, N-adamantyl-N'-dodecylurea (ADU), to DOCA-salt hypertensive rats to determine possible antihypertensive and cardiovascular protective roles by measurement of the changes in cardiovascular structure and function.

METHODS

Ethical Clearance

All experimentation was approved by the Animal Experimentation Ethics Committee of The University of Queensland under the guidelines of the National Health and Medical Research Council of Australia.

N-Adamantyl-N'-Dodecylurea

To a stirred solution of 0.61 g (3.3 mmol) of dodecylamine in 5 mL of hexanes was added 0.53 g (3.0 mmol) of adamantyl isocyanate dissolved in 5 mL of hexane. After stirring at room temperature for 1 h, a white solid was obtained, which was recrystallized twice from hexanes. The resulting white crystal (1.05 g; yield: 97%) had a melting point of 104.0–105.0°C. $^1\text{H-NMR}$: δ (CDCl₃) 0.88 (3 H, t, J = 6.9 Hz), 1.16–1.36 (16 H, m), 1.44–1.49 (2 H, m), 1.58–1.59 (2 H, m), 1.66–1.68 (6 H, m), 1.90–1.96 (6H, m), 2.05–2.07 (3 H, m), 3.09 (2 H, q, J = 6.9 Hz), 4.02 (2H, bs) ppm. Liquid chromatography (LC)-mass spectrometry (MS) m/z (relative intensity): 135.3 (100, $[\text{M}-\text{C}_{13}\text{H}_{27}\text{N}_2\text{O}]^+$), 186.2 (3 $[\text{M}-\text{C}_{11}\text{H}_{16}\text{NO}+2\text{H}]^+$), 363.3 (9, $[\text{M}+\text{H}]^+$). The chemical structure of ADU is displayed in Fig. 1. ADU inhibited mouse and human sEH by 50% at $0.05 \pm 0.01 \mu\text{M}$ and $0.10 \pm 0.01 \mu\text{M}$ respectively, as measured by methods described previously (17). ADU (500 μM) did not inhibit microsomal epoxide hydrolase, other cytochrome p450 enzymes or esterases.

DOCA-Salt Hypertensive Rats

Male Wistar rats weighing 300–330 g (~8 wk old) were obtained from the Central Animal Breeding House of The University of Queensland. All rats were uninephrectomized under anesthesia with intraperitoneal tiletamine (25 mg/kg) and zolazepam (25 mg/kg) (Zoletil®) combined with xylazine (10 mg/kg) (Ilium Xylazil®). Kidneys were visualized by a left lateral abdominal incision. The left kidney was removed after ligation of adjoining renal vasculature and ureter with sutures. The capsule was removed from the left kidney, which was then weighed. Uninephrectomized rats were given either no further treatment (UNX rats) or 1% NaCl in the drinking water with subcutaneous injections of DOCA (25mg in 0.4 mL dimethylformamide every fourth day) (DOCA-salt rats). After 14 d, rats received daily subcutaneous injections of ADU (10mg/kg) for a further 14 d. The dosage of ADU was chosen based on previous studies using related and similarly potent sEH inhibitors in rats (19,21,22). Experiments were performed 28 d after surgery.

Assessment of Physiological Parameters

Systolic blood pressure was measured by tail-cuff plethysmography in rats lightly anesthetized with intraperitoneal tiletamine (10 mg/kg) and zolazepam (10 mg/kg). Rats were euthanized with pentobarbitone (200 mg/kg intraperitoneally). Blood was collected from the abdominal vena cava, just caudal to the insertion of renal veins, into heparinized tubes, centrifuged, and the plasma immediately frozen. Plasma sodium and potassium concentrations were measured by flame photometry. The heart and right kidney were removed and weighed immediately after death and their weights expressed as a ratio of the tissue weight (mg) to the total body weight (g).

Isolated Langendorff Heart Preparation

Rats were anaesthetized with sodium pentobarbitone (100 mg/kg intraperitoneally) and heparin (200 IU) was administered via the femoral vein. After allowing two minutes for the heparin to circulate, the heart was excised and placed in cooled (0°C) crystalloid perfusate (modified Krebs-Henseleit solution of the following composition in mM: NaCl 119.1, KCl 4.75, MgSO₄ 1.19, KH₂PO₄ 1.19, CaCl₂ 2.16, NaHCO₃ 25.0, glucose 11.0). A cannula was then placed in the heart with its tip immediately above the coronary ostia of the aortic stump. The cannula was used to perfuse the heart in a non-recirculating Langendorff fashion at 100cm of hydrostatic pressure. The perfusate temperature was maintained at 37°C and bubbled with 95% O₂/5% CO₂. The apex of the heart was pierced to facilitate thebesian drainage and paced at 250 bpm.

Left-ventricular developed pressure was measured using a balloon catheter inserted into the left ventricle through the mitral orifice. The catheter was connected via a three-way tap to a micrometer syringe and to a MLT844 Physiological Pressure Transducer (ADInstruments) and PowerLab data acquisition unit (ADInstruments). The outer diameter of the catheter was similar to the mitral annulus to prevent ejection of the balloon during the systolic phase. After a 5-min stabilization period, steady-state left-ventricular pressure was recorded from isovolumetrically beating hearts. Increments in balloon volume were applied to the heart with left ventricular end-diastolic pressure recorded at approx 0, 5, 10, 15, 20, and 30 mmHg. At the end of the experiment, the atria and right ventricle were dissected away leaving the left ventricle and septum, which were blotted dry then weighed. Myocardial diastolic stiffness was calculated as the diastolic stiffness constant (k , dimensionless), the slope of the linear relation between tangent elastic modulus (E , dyne/cm²) and stress (σ , dyne/cm²) (23).

Grading of Inflammation in the Left Ventricle

The degree of left-ventricular inflammation was determined by blinded semi-quantitative analysis of hematoxylin and eosin-stained transverse sections. Slides were visualised under a

light microscope with an objective lens of 40× magnification. A zero to four grading scale was used to quantify the degree of inflammatory cell infiltration in the left ventricle. 0, no inflammatory cells present; 1, low level of inflammatory cells throughout the left ventricle; 2, moderate levels of inflammatory cells throughout the left ventricle and concentrated in mild scarring; 3, high levels of inflammatory cells throughout the left ventricle and concentrated in moderate scarring; 4, high levels of inflammatory cells throughout the left ventricle and concentrated in heavy scarring.

Quantification of Left Ventricular Collagen

Collagen content was determined by image analysis of picrosirius red-stained sections of the hearts (24). In brief, transverse sections were stored initially in Telly's fixative (100 mL 70% ethanol; 5 mL glacial acetic acid; 10 mL formaldehyde) for 3 d, then transferred to modified Bouin's solution (85 mL saturated picric acid; 5 mL glacial acetic acid; 10 mL 40% formaldehyde) for 2 d, then stored in 70% ethanol.

Sections were subsequently embedded in wax and sliced into 10-μm sections. These were stained with picrosirius red (0.1% Sirius Red F3BA in picric acid). Slides were left in 0.2% phosphomolybdic acid for 5 min, washed, left in picrosirius red for 90 min, then in 1 mM HCl for 2 min and 70% ethanol for 45 s. The stained sections were mounted with Depex and visualized using a Biorad MRC-1024 confocal laser-scanning microscope with a Red/Texas Red filter with excitation at 568 nm and green emission at 609 nm. Images were acquired with an objective lens of 40× magnification and quantified using NIH-image software (National Institute of Health, MD). At least four areas from each heart were analyzed and collagen levels expressed as a percentage of red area in each image.

Width of Media in Thoracic Aorta

The width of the media in the thoracic aorta of rats was measured by image analysis of picrosirius red-stained sections. Section preparation, staining, image acquisition, and analysis were similar to those mentioned above. Three different areas of each aorta were measured and the results averaged.

Isolated Thoracic Aortic Rings

Thoracic aortic rings (~4 mm in length) were suspended with a resting tension of 10 mN. Cumulative concentration-response curves were performed for noradrenaline and either acetylcholine or sodium nitroprusside in the presence of a submaximal (~70%) contraction to noradrenaline.

Microelectrode Studies of Isolated Left-Ventricular Papillary Muscles

Electrophysiological recordings of cardiac action potentials were obtained by microelectrode single cell impalements of ex vivo, left-ventricular papillary muscles. Rats were euthanized by carbon dioxide inhalation with subsequent exsanguination. The heart was removed and placed in chilled Tyrode's physiological salt solution (in mM: NaCl 136.9, KCl 5.4, MgCl₂·H₂O 1.0, NaH₂PO₄·2H₂O 0.4, NaHCO₃ 22.6, CaCl₂·2H₂O 1.8, glucose 5.5, ascorbic acid 0.3, Na₂-EDTA 0.05) bubbled with 95% O₂/5% CO₂, where the left-ventricular papillary muscles were promptly dissected out. A stainless steel hook was placed through the valvular end of the papillary muscle, and a 30-G needle was used to fix the apical end. The needle was subsequently embedded into a rubber base placed in a 1.0-mL experimental chamber continuously perfused with carbogenated, warm (35±0.5° C) Tyrode's solution at approx 3 mL/min. The hook was attached to a modified sensor element (SensoNor AE801) connected to an amplifier (World Precision Instruments, TBM-4). The muscle was stretched slowly to the required preload (3–5 mN). Papillary contractions were induced by field stimulation (Grass SD-9) via electrodes

on each side of the muscle (stimulation frequency 1 Hz; pulse width 0.5 ms; stimulus strength 20% above threshold). The muscle was allowed to equilibrate for 30 min and was then impaled with a micro-electrode (World Precision Instruments, filamented borosilicate glass, outer diameter 1.5 mm) with a tip resistance of 5–15 M Ω when filled with 3 M KCl. Perfusion and recording then continued for another 30 min. Cardiac action potential parameters measured were cardiac action potential duration (APD) at 20%, 50%, and 90% of repolarization (APD20, ADP50, and APD90 respectively), action potential amplitude and resting membrane potential. The reference electrode was an Ag/AgCl electrode. A Cyto 721 electrometer (World Precision Instruments) was used to record bioelectrical activity. All signals were recorded via a PowerLab 4S data acquisition unit (ADInstruments). Data were acquired, derived and analysed using Chart 4.3 software (ADInstruments).

Data Analysis

All results are given as mean $\pm$ SEM. The negative log EC50 of the increase in force of contraction in mN was determined from the concentration giving half-maximal responses in individual concentration–response curves. These results were analyzed by one-way analysis of variance followed by the Tukey posttest to determine differences between treatment groups; $p < 0.05$ was considered significant.

Drugs

Deoxycorticosterone acetate, 4-aminopyridine, acetylcholine, sodium nitroprusside, and noradrenaline were purchased from Sigma Chemical Company, St Louis, MO. Noradrenaline, sodium nitroprusside and acetylcholine were dissolved in distilled water; ADU and deoxycorticosterone acetate were dissolved in dimethylformamide with mild heating.

RESULTS

Over the 4-wk treatment period, DOCA-salt rats developed significant cardiovascular remodeling shown as ventricular hypertrophy, collagen deposition, endothelial dysfunction, and cardiac action potential duration prolongation (Table 1) (Fig. 2). These rats gained significantly less weight than UNX controls and became hypokalemic with an increased inflammatory cell infiltration as well as an increased diastolic stiffness of the left ventricle (Table 1) (Fig. 3). Treatment with ADU for 2 wk starting 2 wk after surgery prevented any further increase in blood pressure (Fig. 2) and left-ventricular wet weight (Table 1) without changes in blood electrolytes, body weight, inflammatory cell infiltration, collagen deposition, or diastolic stiffness (Table 1). In addition, DOCA-salt rats showed medial hypertrophy, which was prevented by ADU intervention (Fig. 4).

The maximal contractile responses to noradrenaline and relaxant responses to sodium nitroprusside in isolated thoracic aortic rings were unchanged in DOCA-salt rats and also after treatment with ADU (Fig. 5A,C). In contrast, the maximal relaxant responses to acetylcholine were reduced in DOCA-salt rats after 4 wk. ADU treatment normalized this endothelium-dependent relaxation response to acetylcholine in DOCA-salt rats (Fig. 5B).

DOCA-salt treatment caused significant cardiac action potential prolongation at APD90 whereas resting membrane potential and cardiac action potential amplitude were unchanged. These parameters were unchanged by ADU treatment (Table 2).

DISCUSSION

The EETs are metabolites of arachidonic acid that are inactivated by sEH. The high inhibitory potency of the substituted urea compound, ADU, on mouse and human sEH and lack of activity

on cytochrome p450s and esterases suggest that this compound is a highly selective sEH inhibitor. The synergism between the inhibitors of sEH and slow release formulations of the natural EETs supports the hypothesis that these inhibitors are effective by stabilization of these endogenous biological mediators (25). This study demonstrates that administration of ADU lowered systolic blood pressure, normalized vascular endothelial function, and attenuated left-ventricular hypertrophy in the DOCA-salt model of hypertension in rats, supporting a vascular-selective role for sEH in the pathogenesis of this model and a role for EETs in lowering an increased blood pressure.

Sinal et al. (26) first showed that sEH may have a role in blood pressure regulation, reporting that the systolic blood pressure of sEH-knockout male mice was lower, with a resultant reduction in the renal formation of EETs and DHETs, compared with wild-type mice. The development of potent, competitive urea-based sEH inhibitors (17) and their subsequent use in animal models of cardiovascular disease (19,21,22) has highlighted the potential importance of this enzyme in hypertension. As an example, a single dose of N,N'-dicyclohexylurea, another urea-based sEH inhibitor similar to ADU, lowered systolic blood pressure and urinary DHET excretion in the SHR, with the antihypertensive effect lasting less than 24 h (21). Furthermore, treatment with the related compound 1-cyclohexyl-3-dodecyl urea for 4 to 10 d in angiotensin-induced hypertensive rats was effective in reducing blood pressure (19,22). The response to sEH inhibitors is assumed to be due to the resultant increase in plasma EET concentrations (19,21,22). Potential mechanisms for the antihypertensive action of sEH inhibitors such as ADU include direct activation by EETs of vascular smooth muscle potassium channels (27) and inhibition of renal $\text{Na}^+\text{-K}^+\text{-ATPase}$ (28) and $\text{Na}^+\text{-K}^+\text{-2Cl}^-$ cotransporter (29).

Overexpression of sEH may contribute to cardiovascular disease. An increased sEH gene expression and protein abundance have been established in the SHR (21,30) and angiotensin-induced hypertension (19,22). This suggests that overactive conversion of EETs to their corresponding diols could diminish the antihypertensive, anti-inflammatory, and anti-proliferative responses to EETs, contributing to the pathogenesis of cardiovascular disease in these models. Altered sEH enzymatic activity may be responsible for pregnancy-induced hypertension, with dramatic rises observed in the excretion of DHETs in this condition (31). Allelic variation in the sEH gene may have implications in the development of coronary artery calcification (32) and familial hypercholesterolemia (33) and hence atherosclerosis.

The effects of EETs on vascular proliferation are contradictory. The sEH inhibitor 1-cyclohexyl-3-dodecylurea inhibited human vascular smooth muscle cell proliferation in vitro, with no evidence of cellular toxicity or apoptosis in treated cells, an effect mimicked by EETs (18). However, EETs showed mitogenic effects in vascular smooth muscle cells (34). An anti-migratory action of EETs has been suggested in rat aortic smooth muscle cells without pro- or anti-proliferative effects on platelet-derived growth factor (PDGF)-stimulated mitogenesis (6). Vascular hypertrophy and structural remodelling of vessel walls in hypertension exacerbate the condition by increasing systemic vascular resistance (35,36). The decreased vascular remodeling following ADU treatment may be a consequence of the reduced systolic blood pressure or a direct inhibition of vascular smooth muscle cell proliferation.

Endothelial dysfunction, usually shown as a reduced response to acetylcholine, is characteristic of hypertension (37,38), including the DOCA-salt model (39). Reduction in the blood pressure of DOCA-salt animals has resulted in improved endothelium-dependent vasodilator responses (40). Weintraub and associates (41) demonstrated that treatment of coronary endothelial cells with an sEH inhibitor blocked the conversion of EETs to DHETs and subsequently augmented EET incorporation into the phospholipid membrane bilayer. They also demonstrated in the same study that sEH inhibition augmented a 14,15-EET-induced potentiation of endothelium-dependent relaxation to bradykinin in porcine coronary arteries. These results suggest that sEH,

through regulating EET membrane incorporation, may have a direct role in modulating endothelial function. Thus, the normalization of endothelial-dependent responses in the present study may not only be an indirect response to the prevention of an increase in blood pressure, but also a direct effect of sEH inhibition (and enhanced EET levels) on endothelial function. The relative contribution of either mechanism, however, is beyond the scope of this study.

DOCA-salt hypertension in rats is also characterized by excessive collagen deposition (23) and cardiac action potential duration prolongation (42). ADU did not attenuate these responses, suggesting that EETs have no role in these pathophysiological changes.

In summary, we have shown that administration of the selective sEH inhibitor, ADU, to DOCA-salt hypertensive rats prevented further increases in systolic blood pressure, normalized endothelial dysfunction and attenuated some of the associated cardiovascular remodeling, including left-ventricular and aortic medial hypertrophy. Thus, disease-induced modulation of sEH expression and activity may contribute to the pathogenesis of human and animal cardiovascular disease, which suggests that sEH inhibition to increase EET concentrations is a novel and potentially attractive therapeutic approach to the treatment of hypertension.

Acknowledgements

This work was supported by grants from NIEHS R37 ES02710, P42 ES04699, P30 ES05707, and NIH R01 HL59699-06A1. A visiting professorship was provided by the Department of Biochemistry, The University of Queensland, Australia, to B.D.H.

References

1. Fletcher JR. Eicosanoids. Critical agents in the physiological process and cellular injury. *Arch Surg* 1993;128:1192–1196. [PubMed: 8239981]
2. Roman RJ. P-450 metabolites of arachidonic acid in the control of cardiovascular function. *Physiol Rev* 2002;82:131–185. [PubMed: 11773611]
3. Capdevila JH, Falck JR. The CYP P450 arachidonic acid monooxygenases: from cell signaling to blood pressure regulation. *Biochem Biophys Res Commun* 2001;285:571–576. [PubMed: 11453630]
4. Wu S, Chen W, Murphy E, et al. Molecular cloning, expression, and functional significance of a cytochrome P450 highly expressed in rat heart myocytes. *J Biol Chem* 1997;272:12,551–12,559.
5. Node K, Ruan XL, Dai J, et al. Activation of Galpha s mediates induction of tissue-type plasminogen activator gene transcription by epoxyeicosatrienoic acids. *J Biol Chem* 2001;276:15,983–15,989.
6. Sun J, Sui X, Bradbury JA, Zeldin DC, Conte MS, Liao JK. Inhibition of vascular smooth muscle cell migration by cytochrome p450 epoxygenase-derived eicosanoids. *Circ Res* 2002;90:1020–1027. [PubMed: 12016269]
7. Node K, Huo Y, Ruan X, et al. Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. *Science* 1999;285:1276–1279. [PubMed: 10455056]
8. Muthalif MM, Karzoun NA, Gaber L, et al. Angiotensin II-induced hypertension: contribution of Ras GTPase/Mitogen-activated protein kinase and cytochrome P450 metabolites. *Hypertension* 2000;36:604–609. [PubMed: 11040243]
9. Messer-Letienne I, Bernard N, Roman RJ, Sassard J, Benzoni D. Cytochrome P-450 arachidonate metabolite inhibition improves renal function in Lyon hypertensive rats. *Am J Hypertens* 1999;12:398–404. [PubMed: 10232500]
10. Sacerdoti D, Escalante B, Abraham NG, McGiff JC, Levere RD, Schwartzman ML. Treatment with tin prevents the development of hypertension in spontaneously hypertensive rats. *Science* 1989;243:388–390. [PubMed: 2492116]
11. Stec DE, Deng AY, Rapp JP, Roman RJ. Cytochrome P450 4A genotype cosegregates with hypertension in Dahl S rats. *Hypertension* 1996;27:564–568. [PubMed: 8613204]
12. Lapuerta L, Chacos N, Falck JR, Jacobson H, Capdevila JH. Renal microsomal cytochrome P-450 and the oxidative metabolism of arachidonic acid. *Am J Med Sci* 1988;295:275–279. [PubMed: 3364462]

13. Capdevila JH, Wei S, Yan J, et al. Cytochrome P-450 arachidonic acid epoxigenase. Regulatory control of the renal epoxigenase by dietary salt loading. *J Biol Chem* 1992;267:21,720–21,726. [PubMed: 1370444]
14. Makita K, Takahashi K, Karara A, Jacobson HR, Falck JR, Capdevila JH. Experimental and/or genetically controlled alterations of the renal microsomal cytochrome P450 epoxigenase induce hypertension in rats fed a high salt diet. *J Clin Invest* 1994;94:2414–2420. [PubMed: 7989598]
15. Holla VR, Makita K, Zaphiropoulos PG, Capdevila JH. The kidney cytochrome P-450 2C23 arachidonic acid epoxigenase is upregulated during dietary salt loading. *J Clin Invest* 1999;104:751–760. [PubMed: 10491410]
16. Takahashi K, Harris RC, Capdevila JH, et al. Induction of renal arachidonate cytochrome P-450 epoxigenase after uninephrectomy: counterregulation of hyper-filtration. *J Am Soc Nephrol* 1993;3:1496–1500. [PubMed: 8387830]
17. Morisseau C, Goodrow MH, Dowdy D, et al. Potent urea and carbamate inhibitors of soluble epoxide hydrolases. *Proc Natl Acad Sci USA* 1999;96:8849–8854. [PubMed: 10430859]
18. Davis BB, Thompson DA, Howard LL, Morisseau C, Hammock BD, Weiss RH. Inhibitors of soluble epoxide hydrolase attenuate vascular smooth muscle cell proliferation. *Proc Natl Acad Sci USA* 2002;99:2222–2227. [PubMed: 11842228]
19. Imig JD, Zhao X, Capdevila JH, Morisseau C, Hammock BD. Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension. *Hypertension* 2002;39:690–694. [PubMed: 11882632]
20. Yu Z, Davis BB, Morisseau C, et al. Vascular localization of soluble epoxide hydrolase in the human kidney. *Am J Physiol Renal Physiol* 2004;286:F720–F726. [PubMed: 14665429]
21. Yu Z, Xu F, Huse LM, et al. Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids. *Circ Res* 2000;87:992–998. [PubMed: 11090543]
22. Zhao X, Yamamoto T, Newman JW, et al. Soluble epoxide hydrolase inhibition protects the kidney from hypertension-induced damage. *J Am Soc Nephrol* 2004;15:1244–1253. [PubMed: 15100364]
23. Brown L, Duce B, Miric G, Sernia C. Reversal of cardiac fibrosis in deoxycorticosterone acetate-salt hypertensive rats by inhibition of the renin-angiotensin system. *J Am Soc Nephrol* 1999;10(Suppl 11):S143–S148. [PubMed: 9892155]
24. Miric G, Dallemagne C, Endre Z, Margolin S, Taylor SM, Brown L. Reversal of cardiac and renal fibrosis by pirfenidone and spironolactone in streptozotocin-diabetic rats. *Br J Pharmacol* 2001;133:687–694. [PubMed: 11429393]
25. Smith KR, Pinkerton KE, Watanabe T, Pedersen TL, Ma SJ, Hammock BD. Attenuation of tobacco smoke-induced lung inflammation by treatment with a soluble epoxide hydrolase inhibitor. *Proc Natl Acad Sci USA* 2005;102:2186–2191. [PubMed: 15684051]
26. Sinal CJ, Miyata M, Tohkin M, Nagata K, Bend JR, Gonzalez FJ. Targeted disruption of soluble epoxide hydrolase reveals a role in blood pressure regulation. *J Biol Chem* 2000;275:40,504–40,510.
27. Hu S, Kim HS. Activation of K⁺ channel in vascular smooth muscles by cytochrome P450 metabolites of arachidonic acid. *Eur J Pharmacol* 1993;230:215–221. [PubMed: 8422904]
28. Satoh T, Cohen HT, Katz AI. Intracellular signaling in the regulation of renal Na-K-ATPase. II. Role of eicosanoids. *J Clin Invest* 1993;91:409–415. [PubMed: 8381820]
29. He H, Podymow T, Zimpelmann J, Burns KD. NO inhibits Na⁺-K⁺-2Cl⁻ cotransport via a cytochrome P-450-dependent pathway in renal epithelial cells (MMDD1). *Am J Physiol Renal Physiol* 2003;284:F1235–F1244. [PubMed: 12582005]
30. Fornage M, Hinojos CA, Nurowska BW, et al. Polymorphism in soluble epoxide hydrolase and blood pressure in spontaneously hypertensive rats. *Hypertension* 2002;40:485–490. [PubMed: 12364351]
31. Catella F, Lawson JA, Fitzgerald DJ, Fitzgerald GA. Endogenous biosynthesis of arachidonic acid epoxides in humans: increased formation in pregnancy-induced hypertension. *Proc Natl Acad Sci USA* 1990;87:5893–5897. [PubMed: 2198572]
32. Fornage M, Boerwinkle E, Doris PA, Jacobs D, Liu K, Wong ND. Polymorphism of the soluble epoxide hydrolase is associated with coronary artery calcification in African-American subjects: The Coronary Artery Risk Development in Young Adults (CARDIA) study. *Circulation* 2004;109:335–339. [PubMed: 14732757]

33. Sato K, Emi M, Ezura Y, et al. Soluble epoxide hydrolase variant (Glu287Arg) modifies plasma total cholesterol and triglyceride phenotype in familial hypercholesterolemia: intrafamilial association study in an eight-generation hyperlipidemic kindred. *J Hum Genet* 2004;49:29–34. [PubMed: 14673705]
34. Sheu HL, Omata K, Utsumi Y, et al. Epoxyeicosatrienoic acids stimulate the growth of vascular smooth muscle cells. *Adv Prostaglandin Thromboxane Leukot Res* 1995;23:211–213. [PubMed: 7732837]
35. Karam H, Heudes D, Gonzales MF, Loffler BM, Clozel M, Clozel JP. Respective role of humoral factors and blood pressure in aortic remodeling of DOCA hypertensive rats. *Am J Hypertens* 1996;9:991–998. [PubMed: 8896651]
36. Owens GK, Rabinovitch PS, Schwartz SM. Smooth muscle cell hypertrophy versus hyperplasia in hypertension. *Proc Natl Acad Sci USA* 1981;78:7759–7763. [PubMed: 6950415]
37. Konishi M, Su C. Role of endothelium in dilator responses of spontaneously hypertensive rat arteries. *Hypertension* 1983;5:881–886. [PubMed: 6654451]
38. Luscher TF, Raij L, Vanhoutte PM. Endothelium-dependent vascular responses in normotensive and hypertensive Dahl rats. *Hypertension* 1987;9:157–163. [PubMed: 3818012]
39. Van de Voorde J, Leusen I. Endothelium-dependent and independent relaxation of aortic rings from hypertensive rats. *Am J Physiol* 1986;250:H711–H717. [PubMed: 3458379]
40. Nunes VW, Fortes ZB, Nigro D, Carvalho MH, Zorn TM, Scivoletto R. Influence of enalapril on the endothelial function of DOCA-salt hypertensive rats. *Gen Pharmacol* 2000;34:117–125. [PubMed: 10974419]
41. Weintraub NL, Fang X, Kaduce TL, VanRollins M, Chatterjee P, Spector AA. Epoxide hydrolases regulate epoxyeicosatrienoic acid incorporation into coronary endothelial phospholipids. *Am J Physiol* 1999;277:H2098–H2108. [PubMed: 10564166]
42. Coulombe A, Momtaz A, Richer P, Swynghedauw B, Coraboeuf E. Reduction of calcium-independent transient outward potassium current density in DOCA salt hypertrophied rat ventricular myocytes. *Pflugers Arch* 1994;427:47–55. [PubMed: 8058475]

Fig 1.
The chemical structure of N-adamantyl-N'-dodecylurea.

Fig 2.

Effect of soluble epoxide hydrolase inhibition on blood pressure. Data represent the comparison of systolic blood pressure in uninephrectomy (UNX), N-adamantyl-N'-dodecylurea (ADU)-treated UNX, deoxycorticosterone acetate (DOCA)-salt hypertensive, and ADU-treated DOCA-salt hypertensive groups over the 4-wk protocol period. Values are mean $\pm$ SEM; * $p < 0.05$ vs UNX; # $p < 0.05$ vs DOCA-salt (4 wk).

Fig 3.

Effect of soluble epoxide hydrolase inhibition on ventricular remodeling. The panel shows representative confocal microscopy images of hematoxylin and eosin-stained left-ventricular transverse sections at 200 $\times$ magnification from uninephrectomy (UNX) (**A**), N-adamantyl-N'-dodecylurea (ADU)-treated UNX (**B**), deoxycorticosterone acetate (DOCA)-salt (**C**), and ADU-treated DOCA-salt rats (**D**).

Fig 4.

Effect of soluble epoxide hydrolase inhibition on vascular remodeling. The panel shows representative confocal microscopy images of thoracic aorta cross-sections at 400× magnification from uninephrectomy (UNX) (A), N-adamantyl-N'-dodecylurea (ADU)-treated UNX (B), deoxycorticosterone acetate (DOCA)-salt (C), and ADU-treated DOCA-salt rats (D). The bar graph illustrates the measured aortic medial widths. Values are mean ± SEM; *p < 0.05 vs UNX; #p < 0.05 vs DOCA-salt (4 wk).

Fig 5.

Concentration–response curves to noradrenaline (**A**) for uninephrectomy (UNX) (open square, $-\log EC_{50} 7.4 \pm 0.1$, $n = 14$), N-adamantyl-N'-dodecylurea (ADU)-treated UNX (filled square, $-\log EC_{50} 7.5 \pm 0.1$, $n = 12$), 2 wk deoxycorticosterone acetate (DOCA)-salt (filled circle, $-\log EC_{50} 7.7 \pm 0.1$, $n = 13$), DOCA-salt (open triangle, $-\log EC_{50} 8.0 \pm 0.1^*$, $n = 18$) and ADU-treated DOCA-salt (filled triangle, $-\log EC_{50} 7.8 \pm 0.1^*$, $n = 13$). Concentration–response curves to acetylcholine (**B**) for UNX (open square, $-\log EC_{50} 6.5 \pm 0.2$, $n = 14$), ADU-treated UNX (filled square, $-\log EC_{50} 6.7 \pm 0.2$, $n = 11$), 2 wk DOCA-salt (filled circle, $-\log EC_{50} 6.6 \pm 0.1$, $n = 13$), DOCA-salt (open triangle, $-\log EC_{50} 6.6 \pm 0.1$, $n = 18$) and ADU-treated DOCA-salt (filled triangle, $-\log EC_{50} 6.6 \pm 0.1$, $n = 13$). Concentration–response

curves to sodium nitroprusside (**C**) for UNX (open square, $-\log EC_{50} 7.2 \pm 0.1$, $n = 14$), ADU-treated UNX (filled square, $-\log EC_{50} 7.2 \pm 0.1$, $n = 13$), 2 wk DOCA-salt (filled circle, $-\log EC_{50} 7.4 \pm 0.1$, $n = 12$), DOCA-salt (open triangle, $-\log EC_{50} 7.1 \pm 0.1$, $n = 18$) and ADU-treated DOCA-salt (filled triangle, $-\log EC_{50} 7.4 \pm 0.1$, $n = 13$); * $p < 0.05$ vs UNX; # $p < 0.05$ vs DOCA-salt (4 wk).

Table 1

Physiological Parameters in Uninephrectomy (UNX), Deoxycorticosterone Acetate (DOCA)-Salt, and N-adamantyl-N'-dodecylurea (ADU)-Treated Rats

	UNX	UNX+ADU	DOCA-salt (2 wk)	DOCA-salt (4 wk)	DOCA-salt +ADU
Initial body weight (g)	321 ± 4 (n = 8)	313 ± 6 (n = 8)	314 ± 2 (n = 12)	321 ± 5 (n = 10)	308 ± 3 (n = 13)
Final body weight(g)	380 ± 7 (n = 8)	383 ± 7 (n = 8)	332 ± 7 ^a (n = 12)	335 ± 6 ^a (n = 10)	314 ± 6 ^a (n = 13)
LV + septum weight relative to body weight (mg/g)	1.99 ± 0.04 (n = 8)	1.85 ± 0.04 (n = 8)	2.27 ± 0.05 ^{a, b} (n = 12)	2.71 ± 0.08 ^a (n = 10)	2.45 ± 0.06 ^{a, b} (n = 13)
LV + septum weight relative to tibial length (g/m)	18.3 ± 0.5 (n = 8)	17.1 ± 0.2 (n = 8)	19.3 ± 0.8 ^b (n = 12)	22.6 ± 0.7 ^a (n = 11)	18.9 ± 0.4 (n = 13)
Kidney weight relative to body weight (mg/g)	5.20 ± 0.28 (n = 8)	5.40 ± 0.15 (n = 8)	7.51 ± 0.25 ^{a, b} (n = 12)	8.85 ± 0.39 ^a (n = 11)	9.46 ± 0.31 ^a (n = 13)
Plasma Na ⁺ concentration (mM)	133.6 ± 1.6 (n = 8)	134.2 ± 1.1 (n = 10)	136.5 ± 0.3 (n = 10)	138.2 ± 0.7 (n = 10)	134.6 ± 1.6 (n = 10)
Plasma K ⁺ concentration (mM)	4.0 ± 0.4 (n = 8)	3.7 ± 0.4 (n = 10)	2.2 ± 0.2 ^a (n = 10)	2.3 ± 0.2 ^a (n = 10)	2.3 ± 0.2 ^a (n = 10)
Inflammatory score	0.67 ± 0.21 (n = 6)	0.36 ± 0.18 (n = 7)	2.36 ± 0.50 ^a (n = 7)	3.08 ± 0.37 ^a (n = 6)	3.14 ± 0.24 ^a (n = 7)
Interstitial fibrosis (%area)	2.61 ± 0.24 (n = 6)	2.70 ± 0.30 (n = 7)	4.38 ± 0.35 ^a (n = 6)	5.41 ± 0.65 ^a (n = 6)	5.21 ± 0.21 ^a (n = 7)
Perivascular Fibrosis (%area)	22.5 ± 1.8 (n = 6)	21.2 ± 1.1 (n = 7)	27.1 ± 0.8 ^a (n = 6)	31.3 ± 1.7 ^a (n = 6)	29.5 ± 1.2 ^a (n = 7)
Diastolic Stiffness Constant (<i>k</i>)	22.5 ± 0.4 (n = 7)	22.4 ± 0.3 (n = 7)	22.1 ± 0.3 (n = 8)	24.8 ± 0.6 ^a (n = 12)	25.9 ± 0.6 ^a (n = 8)

^a p < 0.05 compared to UNX.

^b p < 0.05 compared to DOCA-salt (4 wk).

Table 2

Cardiac Electrophysiological Parameters in Uninephrectomy (UNX), Deoxycorticosterone Acetate (DOCA)-Salt, and N-Adamantyl-N'-Dodecylurea (ADU)-Treated Rats

	UNX	UNX+ADU	DOCA-salt (2 week)	DOCA-salt (4 week)	DOCA-salt +ADU
Resting Membrane Potential (mV)	-76 ± 2 (n = 6)	-77 ± 2 (n = 7)	-68 ± 3 (n = 7)	-71 ± 1 (n = 10)	-74 ± 4 (n = 7)
Cardiac action potential Amplitude (mV)	98 ± 4 (n = 6)	93 ± 3 (n = 7)	87 ± 2 (n = 7)	92 ± 1 (n = 10)	97 ± 4 (n = 7)
APD ₂₀ (ms)	9.5 ± 0.7 (n = 6)	10.3 ± 1.1 (n = 7)	11.7 ± 1.1 (n = 7)	14.5 ± 1.2^a (n = 10)	16.7 ± 1.8^a (n = 7)
APD ₅₀ (ms)	24.0 ± 1.5 (n = 6)	24.5 ± 2.2 (n = 7)	28.8 ± 2.2 (n = 7)	37.3 ± 2.6^a (n = 10)	46.2 ± 5.5^a (n = 7)
APD ₉₀ (ms)	66.6 ± 3.1 (n = 6)	65.7 ± 3.4 (n = 7)	86.0 ± 6.9 (n = 7)	105.3 ± 2.9^a (n = 10)	109.4 ± 5.8^a (n = 7)

^a p < 0.05 compared to UNX.